The peptide motifs of two HLA molecules, B8 and DR3(17), which are associated with autoimmune diseases Including myasthenia gravis, were determined from natural peptide pools using Edman degradation. The majority of HLA-B8 Uganda are nonamere preferentially terminated by leuclne. As a characteristic feature of the HLA-B8 motif, there Is a high degree of conservation of positively charged amlno acids at position 3 and 5, exclusively lyslne at position 3, and lyslne or arglnlne at position 5. Additional evidence for this allele-speclflc mottf is the presence of these features in several viral peptldes recognized by HLA-B8 restricted T cells. The DR3(17) motif Is characterized by four conserved anchor-like positions ordered In an almost symmetrical arrangement, as has been found for DR1 and DR5 motifs. A first hydrophoblc/aromatic anchor three to four residues apart from the N-termlnus (at relative position 1) appears to be a common feature of DR ligands. The second anchor Is an aspartate at relative position 4, which is likely to be the DR3(17)-speclfIc contact site In the groove. Two additional conserved positions closer to the C-termlnus are occupied by charged amlno acids at relative position 6 and by hydrophoblc/aromatic residues at positions 6, 9, or 10. Eight Individual naturally processed DR17 ligands were sequenced and were found to be derived from exogenous proteins and cytoplasmlc membrane receptors. These natural peptldes conform well to the determined motif. A single exchange of the anchor-like positions in a model peptide abrogated binding to DR17+ cells. On the basis of the DR17 motif, peptldes from the acetylchollne receptor (AChR), the autoimmune target In myasthenia gravis, were selected that should contain candidate epltopes for AChR-speclfic T helper cells. Several peptide sequences which were reported to activate T cells from DR3 + Individuals were among this collection.
Introduction
The analysis of peptides released from MHC class I molecules has provided sequence information on natural ligands that revealed allele-specrfic motifs which reflected the structural constraints of the binding groove (1, 2) . In addition, X-ray crystallographic data of class I molecules [HLA-A2 (3), HLA-B27 (4), HLA-Aw68 (5) , and H-2K b (6) ] have directly provided insights on the topography of the binding groove and contact sites of peptides via binding pockets.
Genes of the MHC contribute to the susceptibility to certain autoimmune diseases (7) . Myasthenia gravis, which is one of the first and most completely understood human autoimmune diseases, is mediated by autoantibodies to the acetyicholine receptor (AChR) at the neuromuscular junction. Immunogenicity of AChR, however, is depending on AChR-specific T helper cells, which have been reported to recognize numerous antigenic sites on this multideterminant autoantigen (8) (9) (10) (11) . Especially in young onset cases in Caucasians, this disease shows an association with HLA-B8 and DR3 (17) which are in linkage disequilibrium (12) . In contrast to the majority of HLA alleles, a single genetic variant is known for HLA-B8 and two variants, DR17 and DR18 (13) , are known for DR3.
Despite the body of accumulating data, information is still lacking on the variety of antigenic peptides naturally associated with particular MHC class II molecules, like HLA-DR3, which is frequently but not exclusively used as a restriction molecule by AChR-specific T cells. Here we report on allele-specific motifs of natural peptides released from HLA-B8 and DR3 molecules, and find these motifs to be contained in several antjgenic peptides recognized by HLA-B8 or HLA-DR3 restricted T cells.
Methods

Cell lines and antibodies
Epstein-Barr virus (EBV) transformed human B cells from a local homozygous donor (RUP, HLA-B8, DR17, DR52a) and WT49 cells [HLA-DR17, DR52b (14) ] were grown in RPM11640 medium (Gibco, Eggenstein, Germany) supplemented with 10% FCS (Boehringer-Mannheim, Mannheim, Germany), 20 mM HEPES, 2 mM glutamine and antibiotics, and expanded in roller bottles to 0.5x10 10 -1x10 10 cells.
For precipitation of the HLA-B8 molecule, the mouse mAb SFR8-B6 (lgG2b, obtained from the American Type Culture Collection, Rockville, MD), directed against a public epitope Bw6 (15) , was purified from the hybridoma culture supernatant using Protein A-Sepharose and coupled to CNBr-activated Sepharose 4B (10 mg/ml). HLA-DR17 molecules were purified by immuneaffinity with antibody 16.23 [a generous gift from Dr J. P. Johnson, Institute of Immunology, University of Munich, Germany (16) ], which recognizes HLA-DR17 and HLA-DR52a on RUP cells, and HLA-DR3 but not DR52b present on WT49 cells.
Isolation of peptides associated with HLA-B8 and DR3 molecules
The isolation and separation of HLA-B8 and HLA-DR3 bound self peptides was performed as described (1, 17) with slight modifications. Briefly, EBV-transformed B cells were pelleted and stirred for 45 min in 10-fold cell volume of 1% Nonidet P-40 in PBS containing 0.2 mM phenylmethylsulfonyl fluoride, 1 /tg/ml aprotinine, 5 nM leupeptin, and 1 /tM pepstatin. The lysate was centrifuged at 250 g for 10 min, then at 140,000 g for 45 min. The supernatant was first passed over a Glycine -Sepharose 4B column (mock-column, 1 ml), and subsequently over SFR8 -B6 Sepharose (10 mg/ml), followed by the mAb 16.23 Sepharose (10 mg/ml). All steps were performed at 4°C. The beads were eluted twice with 0.1% trifluoroacetic acid (TFA). The TFApeptide extract from HLA-B8 was dried by vacuum centrifugation and separated by reversed-phase HPLC (Pharmacia, Freiburg, Germany). TFA-peptide extract from DR17 molecules was ultrafiltrated through Centricon 10K filters prior to separation on a narrow bore reversed-phase HPLC column (RPC C2/C18; 2.1 x 100 mm; Pharmacia) using the SMART system (Pharmacia). Starting solution was 0.1% TFA; the acetonitrile gradient is indicated in Fig. 1 .
Sequencing of peptide mixtures
Peptide pools were analyzed by automated Edman degradation in a pulsed-liquid protein sequencer 477A equipped with an on-line PTH amino acid analyzer 120A (Applied Biosystems, Foster City, CA) as described in detail (1) . Cysteine and tryptophan were routinely not analysed in order to avoid further treatment of the small amounts of isolated peptide pools with derivatizing agents. Most MHC class I ligands, inclusive of HLA-B8, are homogeneous in length and sequencing of pooled peptides resulted in signals for conserved residues focused at one cycle (1) . In contrast, MHC class II ligands are heterogeneous in length; therefore additional criteria were introduced to evaluate pool data from HLA-DR17 associated peptide. An increase in the absolute amount of an individual residue compared with the amount of the previous cycle and the basal level was considered significant if the next cycle confirmed the increase. The initiation of these clusters was assigned to relative positions. An exception to these criteria is proline in cycle 2, which is likely to be unaffected by the ragged ends of HLA-DR ligands (K.Falk etaJ., submitted).
Synthetic peptides
AChR peptide c*310-327 (see Table 6 ) and derivatives were synthesized by the F-moc solid phase method on a peptide synthesizer (model 430 A; Applied Biosystems). The peptides were analyzed by reversed-phase HPLC, amino acid analysis, and electrospray mass spectrometry. Peptides were biotinylated by a 3.5 molar excess of biotinyl-eaminocaproyl-W-hydroxysuccinimide ester (BACNHS, Sigma, St Louis, MO) at 20°C for 2h.
Binding assay
Aliquotsof 100^1 biotinylated a310-327 and derivatives (25/iM final concentration) were added to EBV cells (3 x 10 5 ) in 100 /il RPM11640 and incubated at 37°C for 16 h. After incubation with 20 iA streptavidin (40 /ig/ml; Dianova, Hamburg, Germany) at 4°C for 30 min, cells were subsequently stained with 20 y\ biotinylated phycoerythrin (PE) (40 /ig/ml, Dianova). Each step was followed by two to five washes at 4°C with Hanks balanced salt solution/ 0.1% BSA/0.1% sodium azide. Stained cells were subjected to flow cytometry on a FACS Star-vantage (Becton-Dickinson, Mountain View, CA) and evaluated with the Lysis II program. To measure the relative amount of biotinylated PE bound to DR17, the mean fluorescence was determined from 5000 viable cells. Background values from incubation with BACNHS in the absence of the peptides were subtracted.
Results
The HLA-B8 consensus motif HLA-B8 molecules were isolated by immunoaffinity chromatography from the EBV-transformed homozygous human B cell line RUP. HLA-B8 associated peptides were released by aqueous TFA and further purified by reversed-phase HPLC. Fractions known to contain the majority of natural MHC associated peptides were pooled and sequenced by Edman degradation. Data from three independent experiments (results from experiment 1 are shown in Table 1 ) are summarized in Table 2 . Similar to peptides eluted from other HLA class I molecules [HLA-A*0201 (18) , HLA-A*0205 (18) , HLA-B*2705 (4)], ligands of HLA-B8 have a preferential length of nine amino acids. These peptides have particular sequence characteristics, such as positively charged amino acids, rysine exclusively at position 3, and lysine or arginine at position 5, suggesting two positively charged anchor positions. The only significant residue at the C-terminus is leucine, although the signal is less prominent. It is possible that the anchors in position 3 and 5 provide sufficient binding energy for MHC -peptide interaction and allow a less stringent occupancy at position 9; alternatively the weak terminal leucine could be due to the relative low amount of material. In addition, there is a limited repertoire of amino acids, such as non-polar or small residues like leucine rather than isoleucine, glycine, alanine, and proline at position 2. The remaining positions are occupied by a large number of different residues.
Alignment of peptides containing the HLA-B8 motif
The determined peptide motif, described above, is present in several viral peptides reported to be recognized by HLA-B8 restricted T cells. Sequence alignment of seven viral peptides demonstrated that most fit well to the determined motif (Table  3) . Potential HLA-B8 epitopes from the human AChR are shown in Table 7 .
The HLA-DR 17 consensus motif
HLA-DR17 bound peptides were isolated from two different cell sources expressing DR17 and DR52a (RUP) or DR17 and DR52b (WT49) with the HLA DR3/DR52a specific antibody 16.23. Using DR17/DR52b cells we assured ourselves to distinguish clearly between the DRB1 and DRB3 alleles, and to examine exclusively DR17 associated peptides (Fig. 1) .
The pool sequencing data of the class II peptides demonstrated clear amino acid increases at certain positions ( Raw data from pool sequencing of HLA-B8 ligands. Results are shown from one out of three independent experiments. Underlined values reflect significant changes of amino acid composition as described in Methods. signals indicating conserved positions appeared in clusters over two or three consecutive cycles, interpretable as a consequence of the ragged N-termini of class II associated peptides. The only exception from this rule was found with proline at cycle two, the only cycle where proline is strongly dominant. This feature has also been found with other class II molecules. Therefore, proline at position 2 is believed not to be involved in binding of peptides to HLA-DR17. Moreover, it might be a suitable target for an aminopeptidase N-like activity during antigen processing (K. Falk et al., submitted) .
At the N-terminus, three or four residues precede the first conserved site around the relative position 1 (for clarity, conserved residues of class II ligands are numbered by the relative position, starting at the first conserved cluster of hydrophobic residues, Table 6 ). Hydrophobic or aromatic residues like leucine, isoleucine, phenylalanine, valine, and methionine (and potentially tryptophan, which was routinely not analyzed) are at relative position 1. Similarly, in the last conserved cluster at positions 8, 9, and 10 leucine, tyrosine, and phenylalanine are predominant. Between the first and last hydrophobic/aromatic anchors, the DR17 ligands have two additional conserved positions: relative position 4 is predominantly occupied by aspartate; at relative position 6, there are preferentially lysine and arginine, again charged amino acids, and to a lesser extent polar residues. In conclusion, the HLA-DR17 peptide motif is characterized by four conserved positions, position 1, 4, 6, and 8, 9, or 10 that appear to be arranged almost symmetrically.
Individual DR17 ligands
Eight naturally processed DR17 associated peptides, sequenced from peaks 3, 8, 11, 12, 18, and 19 ( Fig. 1) and two DR17/52a ligands from prominent peaks were found. They were derived from exogenous proteins and membrane-bound receptors (Table 5 ). Their length varied from 12 to 18 amino acids; interestingly, the heterogeneity was more confined to the C-terminus. Nine out of 10 sequenced DR17 associated peptides had a less ragged N-terminus: three or four residues precede the anchor proximate the N-terminus (Table 5) as already interpreted from pool sequencing for the majority of DR17-bound peptides (see the signal of the hydrophobic amino acids at cycles 4 and 5, Table 4 ). All peptides except the peptide from peak 6 showed a perfect fit with the DR17 motif ( Table 5 ). This particular peptide was from the human fau-1 protein, and was also found among Cw4 and DPw4 associated peptides (K. Falk, unpublished results). The ligand nature of this peptide is, therefore, questionable.
Binding of motif peptides to DR17 + cells
In summary, we have defined a unique DR17 motif based on sequencing of natural ligands from peptide pools as well as from individual peptides. The functional relevance of conserved residues as contact sites was further substantiated by binding assays using a synthetic DR17 model peptide. Biotinyl-peptide a310-327 from the human AChR was tested for binding to homozygous EBV-transformed B cells (DR17/DR52b: WT49; DR1:
LG2; DR5/DR52b: CIR). This peptide contains the three potential major anchors at relative positions 1, 4, and 9. Only the potential auxiliary anchor at relative position 6 is missing ( Table   Table 3 33  33  33  34  35  33  33  33 Several peptides known to contain HLA-B8 restricted T cell epitopes were aligned according to the positively charged residues lysine and arginine at position 3 and/or 5. The auxiliary anchor at position 9 and the conserved residue at position 2 were taken into account for peptides that allow multiple alignments.
"Alternative alignments are shown for HIV-1 p17 peptide. b Arg (R), positively charged Dke Lys (K) might be also allowed at position 3 of B8 ligands.
•These peptides fit not perfectly with the B8 motif. Raw data from pool sequencing of DR17 ligands. One out of five independent, highly reproducible experiments is shown. Clusters comprising two or three positions, which had values that were increased by 50 -450% compared with the previous cycle were considered to be significant and were underlined. Summary of pool sequencing analysis of DR17 ligands incorporating resutts of all five experiments. Conserved positions and their relative importance are indicated. The sequences of eight natural DR17 and two DR17/52a associated setf peptides are aligned.
"The peptide contains a single mismatch N-S with the human apolipoprotein B and is obviously derived from bovine apolpoprotein B in fetal caB serum. b These sequences were obtained from prominent peaks of DR17/DR52a associated peptides. c The peptide contains a single mismatch E-D with the human apcdtpoprotein B and is obviously derived from bovine apofipoprotein B in fetal caB serum.
''The peptide from peak 6 of DR17 peptides does not fit to the motif. This peptide was also found among Cw4 and DPw4 peptides (K. Fafk, unpublished resutts). The Bgand nature of this peptide is, therefore, questionable. 10°9 " 9" 22* Amino acids that are part of the motif are shown in bold. At relative positions 8, 9 and 10 other hydrophobe residues than leucine, tyrosine and phenylalanine might be also allowed and for an Individual peptide the usage of a definite position as anchor dose to the C-terminus might be heterogeneous a AChR peptides, which were reported to activate T cells from DR3 + individuals. b This peptide binds also to DR1, DR2, and DR5.
surface (results not shown). Binding of cr310-327 was strongly inhibited with an excess of the unbiotinylated analog (G . Malcherek et al., in preparation) . The exchange of a single anchor residue, valine at position a315, or aspartate at position e*318 by unrelated residues aspartate and alanine, respectively, dramatically reduced the fluorescence intensity to background levels in both experiments (Figure 2) .
Alignment of several DR17 binding peptides is in perfect agreement with the conserved residues at relative position 1 and 4 ( Table 6 ). The two other positions are not always conserved in the peptides reported to be DR3 restricted. High affinity ligand binding, as is presumably the case for naturally processed peptides, is likely to be enabled by the exhaustive use of anchors. We assume that most synthetic peptides aligned in Table 6 are suboptimal DR17 binders. Nevertheless, they all contain aspartate at relative position 4, the residue responsible for specific binding to DR17. The exchange of aspartate against asparagine in peptides decreases the specificity of DR17 binding, i.e. TT830-843 (Table 6 ). This peptide, which was reported to bind to DR17 and also to three other DR molecules (22) , shares two anchor positions except aspartate at relative position 4.
Discussion
Allele-specific peptide motifs have been recently determined for HLA class I molecules, HLA-A*0201, HLA-A*0205, HLA-Aw68, HLA-B*2705, HLA-B*5301, and HLA-B*3501 with anchor positions limited to two positions only, position 2 and/or position 9 (1,2,18 -20) . The HLA-B8 motif is strikingly different from these known HLA motifs with regard to the position and the nature of the anchors. The two major anchors are positively charged lysine residues at position 3 and lysine or arginine residues at position 5. Conserved occupancy was also observed at positions 2 and 9, which are the anchor positions in other HLA molecules. We assume that the peptides are anchored at three sites in the binding cleft of HLA-B8: positions 3, 5, and 9. In particular, position 5 fits into a central pocket of the cleft. The conservation at position 2 seems to be more a spatial constraint to small residues than an auxiliary anchor position. Evidence for this assumption emerged from the X-ray structure of the HLA-B27 and structural modeling (21) . Replacement of Cys67 (B27) for Phe67 (B8) appears to alter strongly the access to the respective binding pocket. Amino acids with a longer side chain, such as arginine, which is a HLA-B27 specific anchor at position 2, might be blocked by the bulky aromatic side chain of Phe67 in H LA-BS. Thus, preferentially smaller residues, such as glycine, alanine, proline, and leucine, are present in the HLA-B8 motif. Replacement of bulky hydrophobic residues (A*0201, A*0205, B*2705) at amino acid 156 by aspartate (B8), appears to shift the acceptable residues at position 3 to the positively charged lysine and emphasizes the significance of position 3 as a major anchor position. Another feature of HLA-B8 ligands is the highly conserved residue at P5 in the center of the ligand. This is an unusual interaction site, that has been observed so far in H-2K b and H-2D b only (1). The central anchor certainly has an effect on 'bulging out' of bound peptides (19) and may limit the length of B8 ligands to nonamers. However, the complementary site to this lysine/arginine anchor at position 5 remains unsolved until 3-D analysis of a HLA-B8 peptide complex is available.
Several different attempts have been made to define peptide motifs of MHC class II molecules (22) (23) (24) (25) (26) (27) (28) (29) . Because of the irregular length of class II associated peptides it was argued that it is impossible to deduce a motif from peptide pools (26) . However, the clear patterns of conserved residues found by pool sequencing of the natural class II ligands of DR17 and DR1/DR5 (K. Falkefa/., submitted) demonstrated that this method is useful to determine class II motifs. First, pool sequencing signals appeared in clusters indicating conserved residues. Narrow clustering over two or three positions indicated that the majority of DR17 ligands have a rather homogeneous N-terminus preceding the proximate anchor by three or four amino acids. These findings are confirmed by nine out of 10 individual ligand sequences determined from prominent peptide peaks. The relative homogeneity in size facilitates the evaluation of sequencing data from DR17 peptide pools and the assignation of significant signals to accurate positions. Indeed, all 10 individual natural peptides agreed with the determined DR17 motif from peptide pools (Table 5) , providing additional evidence in favor of the pool sequencing approach.
The DR17 peptide motif is unique compared with the other known DR motifs and consists of four conserved positions. The N-terminal anchor, at the same position and with similar spacing, was also observed with natural ligand motifs of DR1 and DR5 (K. Falk et al., submitted) as well as in a binding motif for DR1 (27) . Since the occupancy of the first anchor of DR1, DR5, and DR3 is similar, it appears that this first hydrophobic/aromatic anchor is a general feature of natural HLA-DR ligands. In contrast, aspartate at relative position 4 seems to be unique for DR17 and Table 7 . Selected list of potential T cell epitopes from the human nicotinic AChR fitting to the B8 motif
a53-61" a332-340" 06-14" 08-16" 762-70" 664-72°A nchor residues are indicated in bold; auxiliary anchors are underlined, a, 0, 7, 6 refer to subunits of AChR.
"Arg (R), positively charged like Lys (K), might be also allowed at position 3 of B8 ligands. may direct the binding specificity to DR17 molecules, and distinguishes the DR17 motif clearly from the other two known class II motifs. The necessity of two residues, a hydrophobic and a negatively charged residue, for binding to DR17 was also observed in recent studies using variants of a HSP65 peptide, described as a DR17 binder (29) . Using the same peptide and variants of other DR17 binding peptides, others (28) have postulated two additional conserved residues at relative positions 3 and 6, occupied by hydrophobic and positively charged Table 8 . Selected list of potential T cell epitopes from the human nicotinic AChR containing two or more residues of the consensus motif of DR17 LVAK  LIQL  YNLK  SEKI  IVTH  KLGT  LVFY  WVRK  DKKI  IAET  KYVA  MSTK  TDYR  GNFD  ISW  QVTY  VFSS  LQTG  FVFY  VFLL  DHDA  QFVA  GTLV  QEER  CDYR  STMV  CNVL  SVTY  TIEW  PALP  SVLR  SVTY TTNV  KIHI  ADGD  KLGT  NPES  LSIS  FFST  SGKP  AEWK  FMLV  RLSW  IDSL  SDGS  PPGI  VFSS  QTGL  IHIH  LSIF  LSSV  WDA  FIIF  PPDP  PNLR  LWVL  VDGV  PPAI  IFQS  NGEW  SPD  IVLE  KFSS  YPVE  NGEW  SPSR  VAIS residues respectively. In this model, hydrophilic residues were allowed at relative position 4. These studies are at discrepancy with exception of the relative position 1. Thus, binding studies with synthetic peptides have been useful to determine certain aspects of class II -ligand interactions, but did not elucidate the complete motif as demonstrated by analyzing natural ligands of DR17. The natural HLA-DR17 motif as a whole is characterized by four conserved positions that are arranged almost symmetrically: hydrophobic anchors at either end of the motif, probably reflecting ends of the binding cleft, encompass the major DR17 anchor aspartate at position 4 and the polar auxiliary anchor at position 6. Pool sequencing data provided clusters of hydrophobic/aromatic residues at relative positions 8, 9, and 10, which might reflect an alternative usage of anchor positions. Comparisons of sequences from individual DR17 ligands and our binding studies favor relative position 9 being the most commonly used C-terminal anchor.
The DR17 motif is confirmed by sequences of prominent ligands from DR17 and DR17/52a isolates, which were derived from exogenous proteins and cytoplasmic membrane receptors. The latter travel through the endocytic pathways with which MHC class II molecules intersect during transport (30) (31) (32) . A similar fate is likely for apolipoprotein B-100, a ligand of the LDL receptor, which were both represented by DR17-binding peptides (Table  5) . Thus, analyzing naturally processed MHC class II ligands, further motif information can provide insight into the mechanisms of antigen processing.
We investigated the motifs of HLA molecules B8 and DR3, since certain human autoimmune diseases including myasthenia gravis are associated with these alleles. HLA-B8 restricted T cells have not been studied in myasthenia gravis so far. Screening of the AChR sequence for potential HLA-B8 epitopes resulted in only one almost perfect hit and six additional ones which had arginine instead of lysine at position 3 (Table 7) . In an attempt to elucidate the pathogenesis of myasthenia gravis, in vitro studies have been focused on CD4 + T helper cells, part of which used HLA-DR3 as a restriction molecule. The specificity of DR3 restricted T cells can be rapidly mapped using allele specific peptides. Accordingly T cell epitopes can be confirmed by endogenous processing of native or recombinant AChR polypeptides. Screening the sequence of the human AChR, we found 37 candidate peptides from the human AChR fitting to the DR17 motif ( Table 8) . Several of these were reported to activate T cells from DR3
+ individuals (Table 6 ). Screening of DR3 + individuals with such peptides will be useful to study the repertoire of T cells responding to AChR and the contribution and relevance of HLA-DR3 in myasthenia gravis. Detailed information on the DR13(17) ligand motif allows us to determine the residues involved in HLA-DR3(17) binding versus those contacting the TCR. This should provide more insight into the molecular pathogenesis of this disease and other DR3 associated autoimmune diseases. Consequently, this should help to develop specific manipulations that may render T cells tolerant or anergic for autoantigens. This might be of great interest in the therapy of autoimmune diseases.
